scholarly journals Periductal Stromal Sarcoma of the Breast: A Case Report

2021 ◽  
Author(s):  
Elham Nazar ◽  
Zohre Shabanzadeh
Keyword(s):  
Breast Cancer ◽  
Radical Mastectomy ◽  
Phyllodes Tumor ◽  
Pathology Report ◽  
Low Grade ◽  
Case Presentation ◽  
Adjuvant Therapies ◽  
Stromal Sarcoma ◽  
Spindle Cells

Introduction: Periductal Stromal Sarcoma (PSS), especially spindle and epithelioid types, is a rare subtype of the malignant fibroepithelial tumor with benign ductal elements and a sarcomatous stroma composed of spindle cells. The therapeutic management of PSS is based on wide surgery with free margins, and adjuvant therapies are not required. Case Presentation: This report describes a 37-year-old woman who presented to Shariati hospital with a right breast mass for review and a second opinion pathology report. The patient had undergone a radical mastectomy in another hospital three months previously. Histological and immunohistochemical examinations revealed PSS and all dissected lymph nodes were free of tumor. Based on the diagnosis, the patient received no adjuvant treatment (such as chemotherapy or radiotherapy). After nine months of close follow-up examinations, no recurrence was observed. Conclusion: PSS is an extremely rare disease with low-grade sarcomatous behavior, which may evolve into a phyllodes tumor or an entity of breast cancer. Therefore, frequent follow-up examinations are required.

scholarly journals Periductal Stromal Sarcoma of the Breast: A Case Report

2021 ◽  
Author(s):  
Elham Nazar ◽  
Zohre Shabanzadeh
Keyword(s):  
Breast Cancer ◽  
Radical Mastectomy ◽  
Phyllodes Tumor ◽  
Pathology Report ◽  
Low Grade ◽  
Case Presentation ◽  
Adjuvant Therapies ◽  
Stromal Sarcoma ◽  
Spindle Cells

Introduction: Periductal Stromal Sarcoma (PSS), especially spindle and epithelioid types, is a rare subtype of the malignant fibroepithelial tumor with benign ductal elements and a sarcomatous stroma composed of spindle cells. The therapeutic management of PSS is based on wide surgery with free margins, and adjuvant therapies are not required. Case Presentation: This report describes a 37-year-old woman who presented to Shariati hospital with a right breast mass for review and a second opinion pathology report. The patient had undergone a radical mastectomy in another hospital three months previously. Histological and immunohistochemical examinations revealed PSS and all dissected lymph nodes were free of tumor. Based on the diagnosis, the patient received no adjuvant treatment (such as chemotherapy or radiotherapy). After nine months of close follow-up examinations, no recurrence was observed. Conclusion: PSS is an extremely rare disease with low-grade sarcomatous behavior, which may evolve into a phyllodes tumor or an entity of breast cancer. Therefore, frequent follow-up examinations are required.

Low-grade endometrial stromal sarcoma developing in a postmenopausal woman under toremifene treatment for breast cancer

2012 ◽  
Vol 39 (1) ◽  
pp. 424-429 ◽  
Author(s):  
Tomoko Kashiyama ◽  
Katsutoshi Oda ◽  
Kei Kawana ◽  
Takahide Arimoto ◽  
Yukiko Kanetaka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Woman ◽  
Endometrial Stromal Sarcoma ◽  
Low Grade ◽  
Stromal Sarcoma

scholarly journals Aggravated Primary Lymphedema of Contralateral Upper Limb after the Radical Mastectomy: A Case Report

2020 ◽  
Author(s):  
Ying Liu ◽  
Weiren Pan ◽  
Jinghong Guan ◽  
Xiao Long
Keyword(s):  
Breast Cancer ◽  
Upper Limb ◽  
Trauma Surgery ◽  
Radical Mastectomy ◽  
Axillary Lymph ◽  
Contralateral Limb ◽  
Case Presentation ◽  
Secondary Lymphedema ◽  
Primary Lymphedema ◽  
Lymphatic Development

Abstract Background: Breast cancer-related lymphedema is usually characterized by edema of the affected the ipsilateral upper limb and trunk. We report a case of aggravated primary lymphedema in the contralateral limb and trunk after breast cancer resection and axillary lymph node dissection.Case presentation: A 63-year-old female developed right thorax-back and upper limb swelling since childhood. After the modified mastectomy, the swelling of her right chest, back and upper limb increased. While she had no edema of left torso and limb. There was no relevant supplementary examination data because she refused to take lymphoscintigraphy or MRI scan. However, according to her medical history and physical examination, she was preliminarily diagnosed as primary lymphedema, International Society of lymphedema stage 2.Conclusions: Primary lymphedema and secondary lymphedema may be both results of the interaction of multiple factors and can be induced or aggravated by trauma, surgery or other reasons besides the abnormal lymphatic development of individuals.

scholarly journals Is quality of life after mastectomy comparable to that after breast conservation surgery? A 5-year follow up study from Mumbai, India

2019 ◽  
Vol 29 (3) ◽  
pp. 683-692
Author(s):  
K. V. Deepa ◽  
A. Gadgil ◽  
Jenny Löfgren ◽  
S. Mehare ◽  
Prashant Bhandarkar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Breast Conservation ◽  
Radical Mastectomy ◽  
Breast Conservation Surgery ◽  
Breast Cancer Surgery ◽  
Significant Difference ◽  
Domain Scores

Abstract Purpose Breast cancer is the commonest cancer in women worldwide. Surgery is a central part of the treatment. Modified radical mastectomy (MRM) is often replaced by breast conserving therapy (BCT) in high-income countries. MRM is still the standard choice, in low- and middle-income countries (LMICs) as radiotherapy, a mandatory component of BCT is not widely available. It is important to understand whether quality of life (QOL) after MRM is comparable to that after BCT. This has not been studied well in LMICs. We present, 5-year follow-up of QOL scores in breast cancer patients from India. Methods We interviewed women undergoing breast cancer surgery preoperatively, at 6 months after surgery, and at 1 year and 5 years, postoperatively. QOL scores were evaluated using FACT B questionnaire. Average QOL scores of women undergoing BCT were compared with those undergoing MRM. Total scores, domain scores and trends of scores over time were analyzed. Results We interviewed 54 women with a mean age of 53 years (SD 9 ± years). QOL scores in all the women, dipped during the treatment period, in all subscales but improved thereafter and even surpassed the baseline in physical, emotional and breast-specific domains (p < 0.05) at 5 years. At the end of 5 years, there was no statistically significant difference between the MRM and BCT groups in any of the total or domain scores. Conclusion QOL scores in Indian women did not differ significantly between MRM and BCT in the long term. Both options are acceptable in the study setting.

scholarly journals Phyllodes tumor of the breast: a clinic-pathologic study of 77 cases in a Hispanic cohort

2015 ◽  
pp. 104-108 ◽  
Author(s):  
Carlos Andres Ossa Gomez ◽  
Fernando Herazo ◽  
Monica Gil ◽  
Carolina Echeverry ◽  
Gonzalo Angel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Disease Free Survival ◽  
Phyllodes Tumor ◽  
Cancer Registries ◽  
Local Relapse ◽  
Free Survival ◽  
Phyllodes Tumors ◽  
Mean Size ◽  
Reported Data

Introduction: Breast Phyllodes tumors are rare breast tumors present in less than 1% of new cases of breast cancer, usually occurring among middle-aged women (40-50 yrs). Objective: This study shows diagnostic experience, surgical management and follows up of patients with this disease during a period of ten years in a oncology referral center. Methods: Retrospectively, breast cancer registries at the institution were reviewed, identifying 77 patients with Phyllodes tumors between 2002 and 2012, who had been operated on at the Instituto de Cancerología - Clínica Las Américas, in Medellín (Colombia). Clinical and histopathological data belonging to these cases was captured and analyzed and descriptive statistics were used. Results: The follow up median was 22.5 months (IQR: 10.5-60.0), average age was 47.2 yrs (SD: 12.4), mean tumor size was 3.6 cm (SD: 4.6), 88.3% of the patients (68 cases) presented negative margins and none of them received adjuvant chemotherapy. Of the patients with Phyllodes tumors; 33.8% had benign, 31.2% had borderline and 35.0% had malignant tumor. Disease-free survival was 85.8% and overall survival was 94.5%. Discussion: Reported data in this article is in accordance with what has been reported in worldwide literature. In our cohort even the high mean size of the tumors, the risk of local relapse and metastatic disease is low than previously reported in literature. Trials with longer follow up and molecular trials in Phyllodes tumors are necessary to understand the behavior of these tumors in Hispanics population.

Carcinoembryonic Antigen (CEA) in the Follow-Up of Disease-Free Breast Cancer Patients

1982 ◽  
Vol 68 (6) ◽  
pp. 477-480 ◽  
Author(s):  
Andrea Veronesi ◽  
Renato Talamini ◽  
Serenella Longhi ◽  
Diana Crivellari ◽  
Enzo Galligioni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Cancer Patients ◽  
Relapse Rate ◽  
Patient Population ◽  
Prognostic Value ◽  
Radical Mastectomy ◽  
Breast Cancer Patients ◽  
Disease Free

Carcinoembryonic antigen (CEA) assays (2536) were performed in 380 disease-free breast cancer patients after radical mastectomy. In the 334 evaluable patients with 3 or more determinations, the overall relapse rate after a median follow-up of 29 months was 11 %. Of 203 patients with normal CEA values, 19 (9.3 %) relapsed. In the 50 patients with the highest CEA value greater than 20 ng/ml, the relapse rate was 26 %; in the 12 patients with gradually increasing CEA elevations it was 50 %. However, CEA was unable to predict recurrence in N- patients. Premastectomy N+ was significantly associated with greater than 20 ng/ml or gradually increasing CEA values, suggesting the lack of an independent prognostic value of CEA in our patient population.

Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer

2002 ◽  
Vol 347 (16) ◽  
pp. 1227-1232 ◽  
Author(s):  
Umberto Veronesi ◽  
Natale Cascinelli ◽  
Luigi Mariani ◽  
Marco Greco ◽  
Roberto Saccozzi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Randomized Study ◽  
Radical Mastectomy ◽  
Breast Conserving Surgery

Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 3045-3045
Author(s):  
J. Horiguchi ◽  
Y. Koibuchi ◽  
N. Rokutanda ◽  
R. Nagaoka ◽  
M. Kikuchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Pathological Complete Response ◽  
Clinical Stage ◽  
Radical Mastectomy ◽  
Complete Response ◽  
Breast Conserving Surgery ◽  
Weekly Paclitaxel ◽  
Her2 Positive ◽  
Positive Breast Cancer

3045 Background: The purpose of this study is to determine the clinical efficacy of neoadjuvant paclitaxel and trastuzumab in women with advanced breast cancer, with or without metastatic disease. Methods: Patients with HER2-positive breast cancer (clinical stage IIB-IV) were included in this study. The patients received trastuzumab 4mg/kg loading dose intravenously then 2mg/kg weekly and concurrently paclitaxel 80mg/m2 (Day 1, 8, 15) weekly for 4 cycles followed by surgery. Results: Preliminary results from 15 patients are reported. Of these, six patients (40%) had a clinical complete response and nine patients (60%) a clinical partial response. Fourteen of 15 patients received surgery; eight breast-conserving surgery and six modified radical mastectomy. Six patients (43%) had pathological complete response. With a median follow-up of 19 months (range, 5–32 months), these 15 patients are alive. Patients with clinical stage IIB-III breast cancer are alive without any distant metastasis. Conclusion: Combined neoadjuvant weekly paclitaxel and trastuzumab had high clinical and pathological response rates for HER2 overexpressing breast cancer. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document